IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$2.9b

IDEAYA Biosciences Management

Management criteria checks 2/4

IDEAYA Biosciences' CEO is Yujiro Hata, appointed in Jun 2015, has a tenure of 10.75 years. total yearly compensation is $16.93M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth $22.52M. The average tenure of the management team and the board of directors is 2.2 years and 7.4 years respectively.

Key information

Yujiro Hata

Chief executive officer

US$16.9m

Total compensation

CEO salary percentage3.82%
CEO tenure10.8yrs
CEO ownership0.8%
Management average tenure2.2yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Nov 25

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Jul 28
We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 16

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

Apr 13
Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Feb 10

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Jan 03
We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Jul 08

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Jun 18

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

CEO Compensation Analysis

How has Yujiro Hata's remuneration changed compared to IDEAYA Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$114m

Sep 30 2025n/an/a

-US$161m

Jun 30 2025n/an/a

-US$332m

Mar 31 2025n/an/a

-US$307m

Dec 31 2024US$17mUS$646k

-US$274m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

Compensation vs Market: Yujiro's total compensation ($USD16.93M) is above average for companies of similar size in the US market ($USD6.91M).

Compensation vs Earnings: Yujiro's compensation has increased whilst the company is unprofitable.

CEO

Yujiro Hata (51 yo)

10.8yrs
Tenure
US$16,930,872
Compensation

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

Leadership Team

NamePositionTenureCompensationOwnership
Yujiro Hata
Founder10.8yrsUS$16.93m0.79%
$ 22.5m
Andres Briseno
Chief Accounting Officer2.7yrsUS$3.36m0.030%
$ 862.8k
Michael White
Chief Scientific Officer4.3yrsUS$5.38mno data
Darrin Beaupre
Chief Medical Officer3.3yrsUS$6.06mno data
Stuart Dorman
Chief Commercial Officer1.3yrsUS$3.42mno data
Joshua Bleharski
Chief Financial Officerless than a yearno datano data
Paul Barsanti
Chief Technology Officer3.2yrsno datano data
Douglas Snyder
Chief Legal Officer1.5yrsno data0.0024%
$ 67.8k
Francine Zelaya
Senior VP & Head of Human Resources1.8yrsno datano data
Mick O'Quigley
Senior Vice President of Medical Writing & Project Management4yrsno datano data
Daniel Simon
Chief Business Officer1.6yrsno datano data
Jasgit Sachdev
Senior Vice President of Late Phase Clinical Development & Strategy1.2yrsno datano data
2.2yrs
Average Tenure
54.5yo
Average Age

Experienced Management: IDYA's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yujiro Hata
Founder10.8yrsUS$16.93m0.79%
$ 22.5m
Wendy Yarno
Independent Director6.3yrsUS$465.17kno data
Jeffrey Stein
Independent Director10.4yrsUS$472.67k0.069%
$ 2.0m
Frank McCormick
Chair of Scientific Advisory Board7.1yrsno datano data
Scott William Morrison
Independent Director7.7yrsUS$472.67kno data
Catherine Mackey
Independent Director3.9yrsUS$455.17kno data
Trey Ideker
Member of Scientific Advisory Board9.8yrsno datano data
William Sellers
Member of Scientific Advisory Board7.1yrsno datano data
Elizabeth Swisher
Member of Scientific Advisory Board9.8yrsno datano data
Terry Rosen
Independent Chairman of the Board10.2yrsUS$495.17k0.0093%
$ 266.5k
Malcolm Hampton
Independent Director5.8yrsUS$452.67kno data
Karlene Cimprich
Member of Scientific Advisory Board3.3yrsno datano data
7.4yrs
Average Tenure
67yo
Average Age

Experienced Board: IDYA's board of directors are considered experienced (7.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/20 20:41
End of Day Share Price 2026/03/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG